The Impact of β-Blocker Therapy on Peak VO2 in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
American Journal of Cardiovascular Drugs · 19.08.2026
DOI: 10.1007/s40256-026-00822-8 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 19.08.2026. Verfasst von Juliana Giorgi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Sirio Libanes, São Paulo, São Paulo, Brazil. julianagiorgi@hotmail.com. Die Arbeit nennt 29 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure cases and remains without definitive therapy. β-blockers (BB) are frequently prescribed, often extrapolated from HFrEF management, but their benefit in HFpEF is uncertain. By reducing heart rate and contractility, BB may further limit exercise capacity in patients whose cardiac output is rate-dependent. PURPOSE: To systematically evaluate the impact of BB therapy on functional capacity, quality of life, and natriuretic peptide levels in patients with HFpEF. METHODS: A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines (PROSPERO CRD420251229202). PubMed, Embase, and Cochrane databases were searched through November 2025 for randomized and observational studies assessing BB therapy or withdrawal in HFpEF. The primary end point was peak oxygen consumption (VO2 peak). Secondary outcomes included Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Mean or standardized mean differences (95% CI) were pooled using a random-effects model. RESULTS: Five studies comprising 803 patients (525 on BB therapy) were included. BB use was associated with a significant reduction in VO2 peak (MD = -2.02 mL·kg⁻1·min⁻1; 95% CI -3.26 to -0.79; p < 0.01). No significant differences were found in MLHFQ scores (SMD = 0.32; 95% CI -0.57 to 1.21; p = 0.48) or NT-proBNP levels (MD = 130.71 pg/mL; 95% CI -143.27 to 404.69; p = 0.35). CONCLUSIONS: BB therapy was associated with lower objective peak VO2 without consistent effects on patient-reported outcomes or natriuretic peptides. TRIAL REGISTRY: Prospero registration: CRD420251229202.
Autor:innen und Institutionen
- Hospital Sirio Libanes, São Paulo, São Paulo, Brazil. julianagiorgi@hotmail.com.
- Albert Einstein Hospital, São Paulo, São Paulo, Brazil. julianagiorgi@hotmail.com.
- Federal University of Paraíba, João Pessoa, Brazil.
- University Center for the Development of Alto Vale, Rio do Sul, SC, Brazil.
- Pontifical Catholic University of Paraná, Curitiba, Paraná, Brazil.
- Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
Zitieren
APA
Giorgi, J., Batista, P. G., de Souza, M. D. W., Gaelzer, G., Lucena, L., de Oliveira, J. P., Huntermann, R., Molinari, M. E., & Fischer-Bacca, C. O. (2026). The Impact of β-Blocker Therapy on Peak VO2 in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-026-00822-8
Vancouver
Giorgi J, Batista PG, de Souza MDW, Gaelzer G, Lucena L, de Oliveira JP, et al. The Impact of β-Blocker Therapy on Peak VO2 in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs. 2026. doi:10.1007/s40256-026-00822-8
BibTeX
@article{Giorgi2026,
author = {Giorgi, Juliana and Batista, Pedro Gomes and de Souza, Milena Dall Witt and Gaelzer, Giulia and Lucena, Larissa and de Oliveira, Juan Peres and Huntermann, Ramon and Molinari, Maria Eduarda and Fischer-Bacca, Caroline O},
title = {The Impact of β-Blocker Therapy on Peak VO2 in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis},
journal = {American Journal of Cardiovascular Drugs},
year = {2026},
doi = {10.1007/s40256-026-00822-8}
}
EUVIMED